Widespread Small Cell Lung Cancer
Conditions
Brief summary
This study is a multicenter, open label phase I clinical trial aimed at evaluating the pharmacokinetics, tolerability, safety and immunogenicity of SHR-1316 (sc) subcutaneous administration combined with carboplatin and etoposide as first-line treatment for extensive stage small cell lung cancer, and to observe the initial anti-tumor efficacy.
Interventions
DRUGSHR-1316 (sc) Injection
SHR-1316 (sc) injection.
SHR-1316 injection.
DRUGCarboplatin Injection
Carboplatin injection.
Etoposide injection.
Sponsors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with extensive stage small cell lung cancer confirmed by histology or cytology; Has not received first-line systemic therapy or immune checkpoint inhibitor treatment for ES-SCLC in the past. 2. ECOG physical fitness score 0-1 points. 3. According to RECIST v1.1, there must be at least one measurable tumor lesion. 4. Expected survival time ≥ 12 weeks. 5. Having sufficient bone marrow and organ function. 6. Participants must give informed consent to this study prior to the trial and voluntarily sign a written informed consent form.
Exclusion criteria
1. Patients with central nervous system or meningeal metastases. 2. Spinal cord compression that cannot be cured by surgery and/or radiotherapy cannot be included in the study. 3. Patients diagnosed by researchers with uncontrollable tumor related pain. 4. Symptomatic third space effusion requires repeated drainage, such as pericardial effusion, pleural effusion, and abdominal effusion that cannot be controlled by pumping or other treatments. 5. Having undergone major organ surgery (excluding biopsy) or significant trauma within 4 weeks prior to the first use of the investigational drug, or requiring elective surgery during the trial period. 6. History of idiopathic pulmonary fibrosis, organizing pneumonia (such as bronchiolitis obliterans), drug-induced pneumonia, radiation pneumonitis requiring steroid treatment, or clinically significant active pneumonia at screening; Or other moderate to severe lung diseases that seriously affect lung function (patients with a history of radiation pneumonitis (fibrosis) in the radiation area may participate in this study). 7. Severe infections, including but not limited to bacteremia requiring hospitalization and severe pneumonia, were present within 4 weeks prior to the first medication; Within 2 weeks prior to the first medication, there is an active infection with CTCAE ≥ 2 that requires treatment with systemic antibiotics. 8. Individuals with active pulmonary tuberculosis infection detected through medical history or CT examination within the year prior to enrollment, or those with a history of active pulmonary tuberculosis infection more than one year ago but without formal treatment. 9. History of immunodeficiency, including HIV positive, other acquired or congenital immunodeficiency diseases, or organ transplant recipients. 10. Known to have alcohol or drug dependence; Individuals with mental disorders or poor compliance; Pregnant or lactating women; Or the researcher believes that there is a history of other serious systemic diseases or other reasons that make it unsuitable to participate in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SHR-1316 serum trough concentration (Ctrough) | Day1 pre-dose to Day28. |
| Area under the concentration curve from time 0 to 21 days for SHR-1316 (sc) (AUC0-21d) | Day1 pre-dose to Day21. |
| Area under the concentration curve from time 0 to 28 days for SHR-1316 (sc) (AUC0-28d) | Day1 pre-dose to Day28. |
Secondary
| Measure | Time frame |
|---|---|
| Incidence and severity of adverse events (AEs) | About 2 years. |
| Objective Response Rate (ORR) | About 2 years. |
| Duration of Relief (DoR) | About 1.5 years. |
| Maximum Concentration of SHR-1316 (sc) (Cmax) | Day1 pre-dose to Day28. |
| Progression-free Survival (PFS) | About 2 years. |
| Overall Survival (OS) | About 3 years. |
| Disease Control Rate (DCR) | About 2 years. |
| Time to maximum plasma concentration (Tmax) | Day1 pre-dose to Day28. |
| Terminal half-life (t1/2) | Day1 pre-dose to Day28. |
Countries
China
Contacts
Primary ContactRan Zhao
Backup ContactRongfu Mao
Outcome results
None listed